Jubilant receives USFDA nod for immunosuppressant & migraine drugs
The company has received ANDA approval for mycophenolate mofetil and rizatriptan
BS B2B Bureau B2B Connect | Noida (UP)
Jubilant Cadista Pharmaceuticals Inc, the company’s US subsidiary, has received the approval for mycophenolate mofetil USP, 250 mg capsules and 500 mg tablets, while Jubilant Generics Ltd was granted approval for rizatriptan tablets 5 mg and 10 mg.
Mycophenolate mofetil tablet is the generic version of Cellcept (of Roche), an immunosuppressant which is used to help prevent organ rejection in transplants. As per IMS, the current annualised US market size for mycophenolate mofetil USP, 250 mg capsules and 500 mg tablets is $ 245 million.
Also Read
As on September 30, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 05 2015 | 6:33 PM IST